Aptinyx gets $5.6 million grant to study opioid treatment drug

EVANSTON - Aptinyx Inc. said it will receive a $5.6 million grant from the National Institutes of Health to support the development of NYX-783, a drug for the treatment of opioid use disorder.

Aptinyx is a clinical-stage biopharmaceutical company developing therapies for the treatment of nervous system disorders. It said NYX-783 is also in development for the treatment of post-traumatic stress disorder, or PTSD.

The research and development of NYX-783 for opioid use disorder, or OUD, will be aided through the HEAL Initiative grant, administered by the National Institute on Drug Abuse, and awarded to researchers at Yale University School of Medicine. A Phase 1 clinical study of NYX-783 in individuals using opioids will be conducted by researchers at Yale and is expected to commence later this year, Aptinyx said.

"We are excited to be partnering with world-class researchers at Yale in this evaluation of NYX-783, funded by a prestigious and generous grant from NIDA through the NIH HEAL Initiative," said Dr. Andy Kidd, president and chief executive officer at Aptinyx.